LCM
VKTX icon

Landscape Capital Management’s Viking Therapeutics VKTX Stock Holding History

Landscape Capital Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-82,315
Closed -$2.68M – 928
2026
Q1 		$2.68M Buy
+82,315
New +$2.65M 0.17% 186
2025
Q2 		– Sell
-10,003
Closed -$242K – 837
2025
Q1 		$242K Buy
+10,003
New +$316K 0.02% 520
2023
Q2 		– Sell
-41,042
Closed -$683K – 711
2023
Q1 		$683K Sell
41,042
-11,063
-21% -$114K 0.09% 169
2022
Q4 		$490K Buy
+52,105
New +$233K 0.07% 266

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Landscape Capital Management's VKTX Position: Q2 2026 in Review

Landscape Capital Management sold out of Viking Therapeutics (VKTX) in Q2 2026, closing a stake of 82,315 shares — an estimated $2.68M sold.

Landscape Capital Management first reported a position in VKTX in Q4 2022 and held it in 4 quarters. The position peaked at $2.68M in Q1 2026. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Landscape Capital Management reported no remaining Viking Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Landscape Capital Management sold 82,315 Viking Therapeutics shares in Q2 2026, an estimated $2.68M.
  • Landscape Capital Management first reported a position in Viking Therapeutics in Q4 2022 and held it in 4 quarters.
  • Landscape Capital Management's Viking Therapeutics position peaked at $2.68M in Q1 2026.
  • 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Landscape Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.